Home/Filings/4/0001209191-20-060721
4//SEC Filing

Cabell Christopher 4

Accession 0001209191-20-060721

CIK 0001080709other

Filed

Nov 29, 7:00 PM ET

Accepted

Nov 30, 4:01 PM ET

Size

10.1 KB

Accession

0001209191-20-060721

Insider Transaction Report

Form 4
Period: 2020-11-25
Cabell Christopher
EVP, Head of R&D, and CMO
Transactions
  • Exercise/Conversion

    Performance Restricted Stock Unit

    2020-11-252,5005,000 total
    Exp: 2022-01-03Common Stock (2,500 underlying)
  • Tax Payment

    Common Stock

    2020-11-25$65.50/sh1,099$71,9851,401 total
  • Exercise/Conversion

    Common Stock

    2020-11-25+2,5002,500 total
Footnotes (3)
  • [F1]On January 4, 2019, the Reporting Person was granted 5,000 target Performance Restricted Stock Units ("PRSUs"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq "Closing Price" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. 2,500 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount). On Nov. 25, 2020, another 2,500 of the shares subject to the PRSUs vested (50% of the target amount). The final Closing Price target has been met and an additional 5,000 shares will be issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) if the Reporting Person satisfies the subsequent continuing service requirement.
  • [F2]Represents the number of shares withheld by, and surrendered to, Arena relating to tax withholding in connection with the issuance of shares under the PRSUs.
  • [F3]The amount reported in Column 7 of Table II represents the common shares that vested on November 25, 2020. The PRSUs' final Closing Price target has been met and the Reporting Person has a contingent right to receive 5,000 additional common shares if the subsequent continuing service requirement is met.

Issuer

ARENA PHARMACEUTICALS INC

CIK 0001080709

Entity typeother

Related Parties

1
  • filerCIK 0001814928

Filing Metadata

Form type
4
Filed
Nov 29, 7:00 PM ET
Accepted
Nov 30, 4:01 PM ET
Size
10.1 KB